Evidence map›Paper›PMID 37076014›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2023

Fabrication and characterization of bioprints with Lactobacillus crispatus for vaginal application.

Anthony J Kyser, Mohammadali Masigol, Mohamed Y Mahmoud, Mark Ryan, Warren G Lewis, Amanda L Lewis, Hermann B Frieboes, Jill M Steinbach-Rankins

Open access · greenAbstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Drug and therapeutic intravaginal delivery targeting diseases in the female reproductive tract: A mathematical modeling perspective.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Rising role of 3D-printing in delivery of therapeutics for infectious disease.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
  17. Review
  18. The Potential ofPharmaceuticals (Basel, Switzerland) · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Anthony J KyserDepartment of Bioengineering, University of Louisville Speed School of Engineering, Louisville, KY 40202, USA. Electronic address: ajkyse01@louisville.edu.
Mohammadali MasigolCenter for Predictive Medicine, University of Louisville, Louisville, KY 40202, USA. Electronic address: m.masigol@louisville.edu.
Mohamed Y MahmoudCenter for Predictive Medicine, University of Louisville, Louisville, KY 40202, USA; Department of Toxicology and Forensic Medicine, Faculty of Veterinary Medicine, Cairo University, Egypt. Electronic address: myabde01@louisville.edu.
Mark RyanDepartment of Bioengineering, University of Louisville Speed School of Engineering, Louisville, KY 40202, USA. Electronic address: mark.ryan@louisville.edu.
Warren G LewisDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of California San Diego, La Jolla, CA, USA; Glycobiology Research and Training Center, University of California San Diego, La Jolla, CA, USA. Electronic address: wglewis@ucsd.edu.
Amanda L LewisDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of California San Diego, La Jolla, CA, USA; Glycobiology Research and Training Center, University of California San Diego, La Jolla, CA, USA. Electronic address: a1lewis@ucsd.edu.
Hermann B FrieboesDepartment of Bioengineering, University of Louisville Speed School of Engineering, Louisville, KY 40202, USA; Center for Predictive Medicine, University of Louisville, Louisville, KY 40202, USA; Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, USA; UofL Health - Brown Cancer Center, University of Louisville, KY 40202, USA. Electronic address: hbfrie01@louisville.edu.
Jill M Steinbach-RankinsDepartment of Bioengineering, University of Louisville Speed School of Engineering, Louisville, KY 40202, USA; Center for Predictive Medicine, University of Louisville, Louisville, KY 40202, USA; Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, USA; Department of Microbiology and Immunology, University of Louisville School of Medicine, Louisville, KY, USA. Electronic address: jmstei01@louisville.edu.
University of Louisville · USUniversity of California San Diego · US

Funding

3D-bioprinting of sustained- and phased-release antibiotic and probiotic scaffolds to treat bacterial vaginosisR01AI168475 · NIAID · UNIVERSITY OF LOUISVILLE · PI FRIEBOES, HERMANN, LEWIS, AMANDA L. · 2022 to 2025
$3.0M
Understanding the Host-Microbiome-Therapeutic Triad: Implications for Designing Alternative Intravaginal Delivery Platforms to Treat Bacterial VaginosisR01AI139671 · NIAID · UNIVERSITY OF LOUISVILLE · PI FRIEBOES, HERMANN, LEWIS, AMANDA L. · 2019 to 2023
$2.5M
NIAID NIH HHS R01 AI139671NIAID NIH HHS R01 AI168475
6 · The paper itself

Abstract

Bacterial vaginosis (BV) is characterized by low levels of lactobacilli and overgrowth of potential pathogens in the female genital tract. Current antibiotic treatments often fail to treat BV in a sustained manner, and > 50% of women experience recurrence within 6 months post-treatment. Recently, lactobacilli have shown promise for acting as probiotics by offering health benefits in BV. However, as with other active agents, probiotics often require intensive administration schedules incurring difficult user adherence. Three-dimensional (3D)-bioprinting enables fabrication of well-defined architectures with tunable release of active agents, including live mammalian cells, offering the potential for long-acting probiotic delivery. One promising bioink, gelatin alginate has been previously shown to provide structural stability, host compatibility, viable probiotic incorporation, and cellular nutrient diffusion. This study formulates and characterizes 3D-bioprinted Lactobacillus crispatus-containing gelatin alginate scaffolds for gynecologic applications. Different weight to volume (w/v) ratios of gelatin alginate were bioprinted to determine formulations with highest printing resolution, and different crosslinking reagents were evaluated for effect on scaffold integrity via mass loss and swelling measurements. Post-print viability, sustained-release, and vaginal keratinocyte cytotoxicity assays were conducted. A 10:2 (w/v) gelatin alginate formulation was selected based on line continuity and resolution, while degradation and swelling experiments demonstrated greatest structural stability with dual genipin and calcium crosslinking, showing minimal mass loss and swelling over 28 days. 3D-bioprinted L. crispatus-containing scaffolds demonstrated sustained release and proliferation of live bacteria over 28 days, without impacting viability of vaginal epithelial cells. This study provides in vitro evidence for 3D-bioprinted scaffolds as a novel strategy to sustain probiotic delivery with the ultimate goal of restoring vaginal lactobacilli following microbiological disturbances.

Indexed as

Lactobacillus crispatusProbioticsVaginosis, BacterialAlginatesFemaleGelatinHumansLactobacillusVaginaAlginatesGelatin3D bioprintingBacterial vaginosisFemale reproductive tractLactobacillus crispatusProbioticswomen's health

Identifiers

PMID37076014
PMCPMC10696519
OpenAlexW4366463822

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.